Private Equity Firms to Acquire PPD for $3.9 Billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Private Equity Firms to Acquire PPD for $3.9 Billion


ePT--the Electronic Newsletter of Pharmaceutical Technology

The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction. PPD employs more than 11,000 people worldwide and provides contract preclinical and clinical development services to the pharmaceutical and biotechnology sectors.

The Carlyle Group is a global alternative asset manager, and Hellman and Friedman is a private equity firm. Funding for the deal will come from the two companies, along with external debt financing commitments provided by Credit Suisse, JP Morgan, Goldman Sachs, and UBS. The transaction is expected to close in the fourth quarter of 2011.

“Fred Eshelman and PPD’s management team have built a leading and extremely high-quality global research and services organization that will continue to help pharmaceutical and biotech companies develop new drugs at lower costs,” said Karen H. Bechtel, managing director and head of the healthcare group at Carlyle, in a press release. “We look forward to helping expand and enhance PPD’s platform and broad spectrum of therapeutic expertise.”


See related Pharm Tech articles:

PPD Appoints Raymond Hill as CEO (ePT)

What to Watch For in 2011 (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here